Affinage

CRLF1

Cytokine receptor-like factor 1 · UniProt O75462

Length
422 aa
Mass
46.3 kDa
Annotated
2026-06-09
55 papers in source corpus 21 papers cited in narrative 20 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/6 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

CRLF1 is a secreted soluble cytokine receptor subunit that functions as a co-ligand in the CNTF receptor pathway, where it forms a heterodimer with CLCF1/CLC that competes with CNTF for binding to the CNTFR complex (PMID:17436251, PMID:17436252). Loss-of-function mutations that impair CRLF1 secretion cause autosomal-recessive cold-induced sweating syndrome (CISS1)/Crisponi syndrome, with phenotypic severity tracking the degree of secretion defect, establishing a requirement for CRLF1 in autonomic nervous system development (PMID:12509788, PMID:21326283). The oligomeric state of CRLF1 dictates its signaling output: a homodimeric complex drives Smad2/3 signaling to promote chondrogenic differentiation, whereas the CRLF1/CLCF1 heterodimer activates JAK/STAT3 to drive catabolic and senescence-associated programs (PMID:38727293, PMID:39986601). Surface signaling is restrained by the endocytic receptor sorLA, which CRLF1 bridges to CNTFRα to drive CNTFRα internalization and lysosomal degradation (PMID:28117780). In disease contexts CRLF1 is induced by TGF-β1 via SMAD3 and acts as a profibrotic, prohypertrophic effector through ERK1/2 activation in ligamentum flavum and cardiac fibroblasts (PMID:33072735, PMID:37551555), and as a fibroblast-derived paracrine factor it drives cardiomyocyte hypertrophy through LIFR-JAK1/2-STAT3 signaling (PMID:41838796). CRLF1 also acts intracellularly as a component of mTORC2, strengthening the AKT-SIN1 interaction to enhance AKT Ser473 phosphorylation and suppress pyroptosis (PMID:39256356), and promotes proliferation, migration, and EMT across several carcinomas via ERK1/2 and AKT signaling (PMID:29515111, PMID:32982961).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 2002 High

    Established CRLF1 as a disease gene by showing loss-of-function mutations cause an autosomal-recessive disorder, implicating it in autonomic and developmental physiology before its molecular role was understood.

    Evidence Genome-wide linkage mapping and DNA sequencing in affected CISS1 families

    PMID:12509788

    Open questions at the time
    • Did not define the molecular pathway disrupted
    • No biochemical mechanism for how mutations cause disease
  2. 2007 High

    Placed CRLF1 in a defined signaling pathway by showing it heterodimerizes with CLCF1/CLC and competes with CNTF at the CNTFR complex, providing the molecular framework for its disease role.

    Evidence Biochemical characterization, mutation analysis, and patient fibroblast expression assays

    PMID:17436251 PMID:17436252

    Open questions at the time
    • Did not resolve how secretion defects translate into receptor pathway failure in vivo
    • Downstream signaling effectors not detailed
  3. 2011 Medium

    Linked genotype to phenotype mechanistically by demonstrating that the kinetics of mutant CRLF1 secretion, rather than presence of mutation per se, determine clinical severity.

    Evidence Secretion assays of mutant CRLF1 in cells correlated with clinical data across 19 patients

    PMID:21326283

    Open questions at the time
    • Single lab
    • Does not explain tissue-specific manifestations
  4. 2013 Medium

    Revealed a CNTFR-independent function by showing CRLF1 protects neuroblastoma cells against oxidative stress cell-autonomously, indicating roles beyond its canonical co-ligand activity.

    Evidence siRNA knockdown and overexpression with 6-OHDA toxicity assays in differentiated neuroblastoma cells

    PMID:23818941

    Open questions at the time
    • Molecular mediator of protection not identified
    • Single cell type, single lab
  5. 2017 Medium

    Defined a downregulation mechanism by showing CRLF1 bridges CNTFRα to the endocytic receptor sorLA, driving receptor internalization and lysosomal degradation to dampen signaling.

    Evidence Western blotting, lysosomal inhibition, and immunocytochemistry in cells co-expressing sorLA, CNTFRα, and CLF-1

    PMID:28117780

    Open questions at the time
    • Physiological relevance in autonomic tissues not tested
    • Single lab
  6. 2020 Medium

    Established CRLF1 as a TGF-β1/SMAD3-induced profibrotic effector acting through ERK signaling, extending its biology to fibrosis and tissue hypertrophy.

    Evidence Tissue transcriptomics/proteomics, SMAD3 inhibitor studies, and in vivo/in vitro knockdown and overexpression in ligamentum flavum models

    PMID:33072735

    Open questions at the time
    • Mechanism of post-transcriptional ERK enhancement not resolved
    • Single tissue context
  7. 2020 Medium

    Identified MYH9 as a direct binding partner stabilizing CRLF1 and traced an ERK-ETV4-MMP1 axis driving cancer metastasis, defining a concrete oncogenic mechanism.

    Evidence Reciprocal Co-IP, RNA-seq, ChIP, and in vitro/in vivo functional assays in papillary thyroid carcinoma

    PMID:32982961

    Open questions at the time
    • Whether MYH9 interaction relates to secreted vs intracellular CRLF1 unclear
    • Single lab
  8. 2024 Medium

    Uncovered an intracellular function by identifying CRLF1 as an mTORC2 component that strengthens AKT-SIN1 interaction to enhance AKT Ser473 phosphorylation and suppress pyroptosis-driven chemosensitivity.

    Evidence Co-IP, mTORC2 biochemistry, AKT phosphorylation assays, and binding-defective mutants in ovarian cancer cells

    PMID:39256356

    Open questions at the time
    • Reconciliation with secreted CRLF1 biology not addressed
    • Structural basis of AKT-SIN1 bridging not defined
  9. 2024 Medium

    Showed that CRLF1 oligomeric state dictates signaling outcome, with homodimers driving Smad2/3 chondrogenesis and CRLF1/CLC heterodimers driving STAT3 catabolism.

    Evidence Distinct complex assays, pathway immunoblots, and in vivo rabbit osteochondral defect model

    PMID:38727293

    Open questions at the time
    • What controls homo- vs heterodimer assembly in vivo unknown
    • Single lab
  10. 2025 Medium

    Connected the CRLF1/CLCF1 heterodimer to JAK/STAT3-driven cellular senescence and SASP production, implicating it in intervertebral disc degeneration.

    Evidence Co-IP and colocalization, RNA-seq, NPC senescence assays, and in vivo IVDD mouse model

    PMID:39986601

    Open questions at the time
    • Receptor used in NPCs not fully resolved
    • Single lab
  11. 2026 High

    Defined CRLF1 as a fibroblast-derived paracrine driver of cardiomyocyte hypertrophy via LIFR-JAK1/2-STAT3, validated genetically and pharmacologically across species.

    Evidence scRNA-seq, fibroblast-specific Crlf1 ablation, pharmacological STAT3 inhibition, and Myh6 R404Q/+ mouse and human HCM models

    PMID:41838796

    Open questions at the time
    • Whether CLCF1 partnership is required in this context not detailed
    • Upstream inducers in HCM not fully mapped

Open questions

Synthesis pass · forward-looking unresolved questions
  • How CRLF1's distinct activities — secreted co-ligand, sorLA-mediated downregulator, intracellular mTORC2 component, and dimer-state-dependent signaling switch — are coordinated within a single cell or tissue remains unresolved.
  • No structural model integrating secreted and intracellular roles
  • Mechanism partitioning CRLF1 between secretion and cytoplasmic mTORC2 unknown
  • Tissue-specific receptor partner choice not systematically mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 3 GO:0098772 molecular function regulator activity 3 GO:0060089 molecular transducer activity 2
Localization
GO:0005576 extracellular region 3 GO:0005829 cytosol 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-1266738 Developmental Biology 2
Partners
AKTCLCF1CNTFRENO1MYH9SIN1SORLA
Complex memberships
CNTFR complexCRLF1/CLCF1 heterodimermTORC2

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2007 CRLF1 forms a heterodimer complex with cardiotrophin-like cytokine factor 1 (CLCF1/CLC), and this heterodimer competes with ciliary neurotrophic factor (CNTF) for binding to the CNTF receptor (CNTFR) complex, placing CRLF1 in the CNTFR signaling pathway. Biochemical characterization; mutation analysis; mRNA expression in patient fibroblasts by real-time quantitative PCR American journal of human genetics High 17436251 17436252
2002 Loss-of-function mutations in CRLF1 cause cold-induced sweating syndrome (CISS1), an autosomal recessive disorder, indicating that CRLF1 is required for normal developmental and autonomic nervous system function. Genome-wide linkage mapping, candidate region fine-mapping, DNA sequencing in affected families American journal of human genetics High 12509788
2011 Phenotypic severity of CRLF1-associated disorders (Crisponi syndrome vs. CISS1) mainly depends on altered kinetics of secretion of the mutated CRLF1 protein; mutations that more severely impair CRLF1 secretion correlate with more severe clinical outcome. Functional secretion assays of mutant CRLF1 proteins from patient-derived or transfected cells; clinical analysis of 19 patients European journal of human genetics : EJHG Medium 21326283
2013 CRLF1 protects differentiated neuroblastoma cells against 6-hydroxydopamine-induced oxidative stress by a cell-autonomous mechanism that is independent of its known role as a co-ligand for the CNTF receptor (gp130/JAK signaling pathway). Loss-of-function (siRNA knockdown) and gain-of-function (overexpression) in neuroblastoma cells; 6-OHDA toxicity assay; differentiation state comparison PloS one Medium 23818941
2017 CLF-1 (CRLF1) contains a binding site for the endocytic receptor sorLA; sorLA-expressing cells rapidly internalize CLF-1 and CLC:CLF-1, and in cells co-expressing CNTFRα and sorLA, CLF-1 bridges CNTFRα to sorLA, driving CNTFRα internalization and lysosomal degradation, thereby downregulating surface CNTFRα and reducing CLC:CLF-1 signaling. Western blotting, lysosomal enzyme inhibition, immunocytochemistry in cells co-expressing sorLA, CNTFRα, and CLF-1 Journal of visualized experiments : JoVE Medium 28117780
2018 CRLF1 promotes proliferation, migration, invasion, and epithelial-mesenchymal transition in papillary thyroid carcinoma cells by activating the ERK1/2 and AKT signaling pathways; these oncogenic effects are suppressed by MEK inhibitor U0126 or AKT inhibitor MK-2206. Loss-of-function and gain-of-function assays in PTC cell lines; in vitro migration/invasion; in vivo tumor growth; Western blotting of ERK1/2 and AKT phosphorylation; pharmacological inhibition Cell death & disease Medium 29515111
2020 CRLF1 directly binds MYH9, which enhances CRLF1 protein stability; this interaction promotes PTC cell proliferation and metastasis via ERK pathway activation and upregulation of transcription factor ETV4, which in turn binds the MMP1 promoter to induce MMP1 expression. Co-immunoprecipitation (direct binding), RNA-sequencing (ETV4 as downstream target), ChIP assay (ETV4 binding MMP1 promoter), in vitro and in vivo functional assays, Western blotting Frontiers in endocrinology Medium 32982961
2020 TGF-β1 upregulates CRLF1 mRNA expression in ligamentum flavum cells via the SMAD3 pathway; CRLF1 in turn enhances fibrosis via ERK signaling at the post-transcriptional level, and CRLF1 knockdown reduces fibrosis caused by inflammatory cytokines and mechanical stress. In vivo, CRLF1 overexpression causes ligamentum flavum hypertrophy. Transcriptome and proteomics of human LF tissue; immunohistochemistry; SMAD3 pathway inhibitor studies; CRLF1 knockdown and overexpression in vivo (bipedal-standing mouse model) and in vitro Frontiers in cell and developmental biology Medium 33072735
2021 miR-3065-3p directly targets and suppresses CRLF1 mRNA (validated by luciferase reporter assay), and CRLF1 acts downstream of miR-3065-3p to inhibit stemness in colorectal cancer; CRLF1 knockdown promotes, and its overexpression restores, the pro-stemness effects regulated by this miRNA. Luciferase reporter assay for direct miR-3065-3p/CRLF1 interaction; gain/loss-of-function in colorectal cancer cell lines and orthotopic xenograft; stemness markers (NANOG, OCT4, SOX2, ALDH activity, sphere formation) Journal of translational medicine Medium 34656128
2021 CRLF1 is a direct target of miR-320 in bone marrow-derived mesenchymal stem cells (BMSCs); suppression of CRLF1 promotes chondrogenic differentiation of BMSCs and protects cartilage from OA damage; miR-320 overexpression reverses CRLF1-driven inhibition of chondrogenesis and promotion of apoptosis. Luciferase reporter assay; miR-320 overexpression; CRLF1 knockdown; chondrogenic differentiation assays in BMSCs; DMM mouse OA model Molecular medicine (Cambridge, Mass.) Medium 34551709
2023 Cardiac fibrosis induced by TGF-β1 upregulates CRLF1 expression through the SMAD-dependent (not SMAD-independent) signaling pathway; CRLF1 then promotes cardiac fibroblast viability, collagen production, proliferation, and myofibroblast transformation by activating the ERK1/2 signaling pathway. Gain- and loss-of-function in neonatal mouse cardiac fibroblasts; ERK1/2 inhibitor; SMAD-dependent and SMAD-independent TGF-β1 pathway inhibitors; Western blotting Journal of Zhejiang University. Science. B Medium 37551555
2024 CRLF1 is a novel component of the mTORC2 complex; it enhances AKT Ser473 phosphorylation by strengthening the interaction between AKT and SIN1, thereby inhibiting the ASK1-JNK-caspase-3-gasdermin E pyroptotic pathway and conferring chemoresistance in ovarian cancer. Binding-defective CRLF1 variants impair AKT-SIN1 interaction and promote pyroptosis. Co-immunoprecipitation (AKT-SIN1 interaction), mTORC2 complex biochemistry, AKT Ser473 phosphorylation assays, gain/loss-of-function with binding-defective mutants, pyroptosis assays, in vitro chemosensitivity assays Cell death & disease Medium 39256356
2024 A homodimeric CRLF1 complex stimulates chondrogenic differentiation of BMSCs via Smad2/3 signaling, while a heterodimeric CRLF1/CLC (CLCF1) complex stimulates catabolic events in chondrocytes via STAT3 activation, demonstrating that the oligomeric state of CRLF1 determines its downstream signaling outcome. CRLF1 overexpression in BMSCs (homodimer secretion confirmed), chondrogenic differentiation assays (alcian blue staining, gene expression), immunoblot for Smad2/3 and STAT3 signaling, interleukin-1β-treated chondrocyte cell line, in vivo rabbit femoral osteochondral defect model Cells Medium 38727293
2025 The CRLF1/CLCF1 heterodimer activates JAK/STAT3 signaling in nucleus pulposus cells, enhancing production of senescence-associated secretory phenotype (SASP) factors and accelerating cell senescence; CRLF1 knockdown reduces extracellular matrix degradation and alleviates intervertebral disc degeneration in vivo. Fluorescence colocalization and co-immunoprecipitation (CRLF1-CLCF1 heterodimer); RNA-seq; in vitro NPC senescence assays; in vivo IVDD mouse model; pain-behavior tests Osteoarthritis and cartilage Medium 39986601
2017 CRLF1 mutations causing familial achalasia result in severely impaired CRLF1 protein secretion from transfected cells, consistent with the secretion-defect mechanism identified in CS/CISS1, and extending the phenotypic spectrum of CRLF1-related disorders to isolated achalasia. Next-generation sequencing; co-immunoprecipitation/secretion assay in transfected cells for the novel c.178T>A (p.Cys60Ser) variant Clinical genetics Low 27976805
2023 The lncRNA MIR22HG suppresses chondrogenic differentiation of human adipose-derived stem cells by binding to CTCF, which then binds the CRLF1 promoter to upregulate CRLF1 expression; inhibition of CRLF1 reverses the anti-chondrogenic effect of MIR22HG. RNA pulldown / RIP for MIR22HG-CTCF interaction; ChIP for CTCF binding to CRLF1 promoter; gain/loss-of-function; chondrogenic differentiation markers Functional & integrative genomics Low 37910254
2024 ENO1 and CRLF1 physically interact (co-immunoprecipitation and co-immunofluorescence), and ENO1 silencing protects against IL-1β-induced chondrocyte inflammation, apoptosis, and matrix degradation; CRLF1 overexpression reverses ENO1 knockdown effects, placing ENO1 upstream of CRLF1 in OA chondrocyte pathology. Co-immunoprecipitation; immunofluorescence; siRNA knockdown and overexpression in IL-1β-stimulated C-28/I2 chondrocytes; NF-κB pathway assays Tissue & cell Low 39116531
2026 CRLF1, predominantly secreted by activated cardiac fibroblasts, acts as a paracrine factor driving cardiomyocyte hypertrophy by activating the LIFR-JAK1/2-STAT3 signaling cascade; genetic ablation of Crlf1 in fibroblasts or pharmacological inhibition of downstream STAT3 signaling markedly attenuates hypertrophic cardiomyopathy phenotypes in mouse and human HCM models. Single-cell RNA sequencing (cellular source identification); bulk RNA-seq and WGCNA; gain- and loss-of-function studies; Myh6 R404Q/+ mouse model; in vitro human cardiomyocyte assays; pharmacological pathway inhibition Circulation High 41838796
2024 CRLF1 promotes prostate cancer cell growth and invasion via upregulation of COMP (cartilage oligomeric matrix protein), which activates the FAK/PI3K/AKT signaling cascade; COMP knockdown abrogates the cancer-promoting effects of CRLF1 overexpression. Bioinformatics (protein interaction networks, TCGA); qRT-PCR and Western blot; Transwell invasion, CCK-8, wound healing assays; in vivo xenograft; genetic perturbation (OE and KD) of CRLF1 and COMP Cancers Low 42122189
2026 ZBTB7A transcriptionally activates CRLF1 expression in ovarian cancer cells; CRLF1 knockdown abrogates ZBTB7A-induced cell proliferation and migration, defining a functional ZBTB7A/CRLF1 oncogenic axis. Transcriptomic analyses; RNA interference and overexpression functional assays; proliferation, clonogenic, migration assays Oncology reports Low 41891980

Source papers

Stage 0 corpus · 55 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2007 Crisponi syndrome is caused by mutations in the CRLF1 gene and is allelic to cold-induced sweating syndrome type 1. American journal of human genetics 75 17436252
2007 Mutations in cytokine receptor-like factor 1 (CRLF1) account for both Crisponi and cold-induced sweating syndromes. American journal of human genetics 55 17436251
2018 CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways. Cell death & disease 45 29515111
2022 CRLF1 and CLCF1 in Development, Health and Disease. International journal of molecular sciences 44 35055176
2002 Cold-induced sweating syndrome is caused by mutations in the CRLF1 gene. American journal of human genetics 44 12509788
2011 Differential secretion of the mutated protein is a major component affecting phenotypic severity in CRLF1-associated disorders. European journal of human genetics : EJHG 38 21326283
2020 CRLF1 Is a Key Regulator in the Ligamentum Flavum Hypertrophy. Frontiers in cell and developmental biology 36 33072735
1996 Is chromosome in situ suppression (CISS) hybridization suited as a predictive test for intrinsic radiosensitivity in cancer patients? International journal of oncology 32 21544417
2016 Bi-allelic Mutations in KLHL7 Cause a Crisponi/CISS1-like Phenotype Associated with Early-Onset Retinitis Pigmentosa. American journal of human genetics 30 27392078
2020 CRLF1-MYH9 Interaction Regulates Proliferation and Metastasis of Papillary Thyroid Carcinoma Through the ERK/ETV4 Axis. Frontiers in endocrinology 29 32982961
2010 Cold-induced sweating syndrome: CISS1 and CISS2: manifestations from infancy to adulthood. Four new cases. Journal of the neurological sciences 26 20400119
2021 miR-3065-3p promotes stemness and metastasis by targeting CRLF1 in colorectal cancer. Journal of translational medicine 25 34656128
2014 Expanding the mutational spectrum of CRLF1 in Crisponi/CISS1 syndrome. Human mutation 20 24488861
2013 Cytokine receptor-like factor 1 (CRLF1) protects against 6-hydroxydopamine toxicity independent of the gp130/JAK signaling pathway. PloS one 18 23818941
2018 Preserved Cochlear CISS Signal is a Predictor for Hearing Preservation in Patients Treated for Vestibular Schwannoma With Stereotactic Radiosurgery. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 17 29561382
2024 CRLF1 bridges AKT and mTORC2 through SIN1 to inhibit pyroptosis and enhance chemo-resistance in ovarian cancer. Cell death & disease 15 39256356
2010 Cold-induced sweating syndrome with neonatal features of Crisponi syndrome: longitudinal observation of a patient homozygous for a CRLF1 mutation. American journal of medical genetics. Part A 15 20186812
2021 Suppression of CRLF1 promotes the chondrogenic differentiation of bone marrow-derived mesenchymal stem and protects cartilage tissue from damage in osteoarthritis via activation of miR-320. Molecular medicine (Cambridge, Mass.) 14 34551709
1994 Familial translocation (X;3) (p22.3;p23): chromosomal in situ suppression (CISS) hybridization and inactivation pattern study. Clinical genetics 12 7889646
1991 Detection of APC region-specific signals by nonisotopic chromosomal in situ suppression (CISS)-hybridization using a microdissection library as a probe. Human genetics 12 1652549
2023 Cytokine receptor-like factor 1 (CRLF1) promotes cardiac fibrosis via ERK1/2 signaling pathway. Journal of Zhejiang University. Science. B 10 37551555
2025 CRLF1/CLCF1 heterodimer involvement in intervertebral disc degeneration via exacerbation of extracellular matrix degradation and nucleus pulposus cell senescence. Osteoarthritis and cartilage 9 39986601
2024 Tobacco smoking is associated with sex- and plaque-type specific upregulation of CRLF1 in atherosclerotic lesions. Atherosclerosis 9 39137621
2018 Bi-allelic c.181_183delTGT in BTB domain of KLHL7 is associated with overlapping phenotypes of Crisponi/CISS1-like and Bohring-Opitz like syndrome. European journal of medical genetics 9 30142437
2012 Multiple small hyperintense lesions in the subcortical white matter on cranial MR images in two Turkish brothers with cold-induced sweating syndrome caused by a novel missense mutation in the CRLF1 gene. Brain & development 9 23026229
2012 Novel CRLF1 gene mutation in a newborn infant diagnosed with Crisponi syndrome. Congenital anomalies 9 23181498
2020 Identification and Reactivity of s-cis,s-cis-Dihydroxycarbene, a New [CH2O2] Intermediate. Journal of the American Chemical Society 8 33166464
2013 Crisponi syndrome: a new mutation in CRLF1 gene associated with moderate outcome. Genetic counseling (Geneva, Switzerland) 8 24032286
2023 Light-Amplified CISS-Based Hybrid QD-DNA Impedimetric Device for DNA Hybridization Detection. Analytical chemistry 7 36749750
2023 Spin-dependent electrified protein interfaces for probing the CISS effect. The Journal of chemical physics 7 37439472
2017 Mutations in CRLF1 cause familial achalasia. Clinical genetics 7 27976805
2011 Homozygous mutation of CRLF-1 gene in a Turkish newborn with Crisponi syndrome. Clinical dysmorphology 7 21691203
2024 ENO1 regulates IL-1β-induced chondrocyte inflammation, apoptosis and matrix degradation possibly through the potential binding to CRLF1. Tissue & cell 6 39116531
2013 Cold-induced sweating syndrome type 1, with a CRLF1 level mutation, previously associated with Crisponi syndrome. Dermatology (Basel, Switzerland) 6 24008591
1993 A retrospective CISS hybridization analysis of a case with de novo translocation t(18;22) resulting in an 18p- syndrome. Clinical genetics 6 8370154
2023 Long non-coding RNA MIR22HG suppresses the chondrogenic differentiation of human adipose-derived stem cells by interacting with CTCF to upregulate CRLF1. Functional & integrative genomics 5 37910254
2022 CISS-Based Label-Free Novel Electrochemical Impedimetric Detection of UVC-Induced DNA Damage. ACS omega 5 36312421
1982 The rate of s-cis/s-trans isomerization in angiotensin II is at least 70-fold greater than in His-Pro and is not rate limiting in receptor binding. International journal of peptide and protein research 5 7118436
2024 Cytokine Receptor-like Factor 1 (CRLF1) and Its Role in Osteochondral Repair. Cells 4 38727293
2016 Crisponi/CISS1 syndrome: A case series. American journal of medical genetics. Part A 4 26804344
2014 A new Turkish infant with clinical features of CS/CISS1 syndrome and homozygous CRLF1 mutation. European journal of medical genetics 4 24613578
1991 Characterization of marker chromosomes in Namalva cells by chromosomal in situ suppression (CISS) hybridization and R-banding. Genes, chromosomes & cancer 4 1797087
2024 Identification and validation of CRLF1 and NRG1 as immune-related signatures in hypertrophic scar. Genomics 3 38262564
2022 Novel Mutations in CRLF1: Case Reports with Crisponi Syndrome. Indian journal of pediatrics 3 35984556
2016 Corneal alterations in Crisponi/CISS1 syndrome: A slit-lamp biomicroscopy and in vivo confocal microscopy corneal report. Ophthalmic genetics 3 27054527
2024 Inhibition of CRLF1 expression by miR-8485 alleviates IL-1β-induced chondrocyte inflammation, apoptosis, and extracellular matrix degradation. International immunopharmacology 2 39580860
2022 Clinical and molecular genetic findings of Crisponi/cold-induced sweating syndrome (CS/CISS) spectrum in patients from Turkey. Clinical genetics 2 35699517
2021 Three new cases of Crisponi /cold induced sweating syndrome (CS/CISS1) in Turkish families. European journal of medical genetics 2 33910095
2019 Interdural high signal on CISS sequence: an alternative CSF pathway? Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2 30613855
2024 The role of cytokine receptor-like factor 1 (CRLF1) in facet joint osteoarthritis pathogenesis. Experimental gerontology 1 39128688
2017 SorLA and CLC:CLF-1-dependent Downregulation of CNTFRα as Demonstrated by Western Blotting, Inhibition of Lysosomal Enzymes, and Immunocytochemistry. Journal of visualized experiments : JoVE 1 28117780
2026 CRLF1 Secreted by Cardiac Fibroblasts Promotes Human Hypertrophic Cardiomyopathy. Circulation 0 41838796
2026 ZBTB7A promotes malignant phenotypes in ovarian cancer through transcriptional activation of CRLF1. Oncology reports 0 41891980
2026 CRLF1 Drives Prostate Cancer Progression via COMP-Mediated Activation of the FAK/PI3K/AKT Signaling Pathway. Cancers 0 42122189
2025 Cavity-mediated enhancement of CISS in DNA junctions. Physical chemistry chemical physics : PCCP 0 40772948

Missed literature

Know a paper Affinage missed for CRLF1? Flag it for the maintainers and the community.

No submissions yet.